PARP inhibitors are small molecule inhibitors that have recently been approved for platinum-sensitive relapsed and platinum-resistant ovarian cancers specifically harboring BRCA1 or BRCA2 mutations [129,132,137]. This evidence concerns the gene BRCA2 and ovarian cancer.